A report by Frost & Sullivan predicts that positron emissiontomography's share of the worldwide market for cancer imagingand therapy equipment will grow rapidly in coming years. PET revenues will constitute 15% of the total market for suchequipment
A report by Frost & Sullivan predicts that positron emissiontomography's share of the worldwide market for cancer imagingand therapy equipment will grow rapidly in coming years.
PET revenues will constitute 15% of the total market for suchequipment by 2000, compared to 1% in 1993. PET's share of revenuesin the cancer imaging and therapy equipment market at that timewill match that of CT, which is expected to decline to 15%, comparedto 24% in 1993.
The market as a whole will grow at a 7% compound annual rate,from $2.74 billion in 1993 to $4.44 billion in 2000, accordingto the report, entitled World Cancer Diagnostic Imaging and TherapeuticEquipment Markets.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.